SIASUN(SZ:300024) Zhi Tong Cai Jing·2025-12-21 12:57Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) has passed the listing hearing on the Hong Kong Stock Exchange, with Morgan Stanley and GF Securities as joint sponsors [1] Company Overview - Precision Medical is an advanced surgical robotics company in the medical device industry, focused on the design, development, and manufacturing of surgical robots. The company has three products at different stages of research and development, targeting the market potential of surgical robots, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots for minimally invasive procedures [3] Product Portfolio - The product lineup includes two core self-developed products: the Precision Multi-Port Laparoscopic Surgical Robot and the Precision Single-Port Laparoscopic Surgical Robot. Additionally, the company has the Precision Bronchoscopy Robot, which is not a core product. The Multi-Port Laparoscopic Surgical Robot is designed for minimally invasive surgeries across urology, gynecology, general surgery, and thoracic surgery, while the Single-Port Laparoscopic Surgical Robot is used for surgeries through a single small incision or natural orifice, applicable in urology, gynecology, and general surgery [3] Market and Regulatory Achievements - Precision Medical is the first company in China and the second globally to obtain regulatory approval for multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots. The company received its first registration approvals from the National Medical Products Administration for these products in December 2022, November 2023, and January 2025, respectively [4] Financial Performance - For the fiscal years ending June 30, 2023, and 2024, Precision Medical reported revenues of approximately RMB 48.04 million and RMB 160 million, respectively. The company incurred losses of approximately RMB 213 million and RMB 219 million for the same periods. The financial data indicates a significant investment in research and development, with R&D expenses of RMB 171.23 million and RMB 226.25 million for the respective years [4][7]